Abstract
Recombinant human TRAIL was successfully expressed in a secreted form in methyltrophic yeast Pichia pastoris induced by methanol. The expressive product was immunoreactive to TRAIL antibody. The addition of the expressive product into cultured human lung cancer cell A549 showed moderate cell death, typical morphological characterization of apoptotic bodies, and DNA fragmentation. This result provided a new method to produce recombinant human TRAIL as a cancer therapeutic drug.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoptosis / drug effects
-
Apoptosis Regulatory Proteins
-
Cell Line, Tumor / drug effects
-
Electroporation
-
Humans
-
Lung Neoplasms / metabolism
-
Membrane Glycoproteins / biosynthesis*
-
Membrane Glycoproteins / metabolism
-
Pichia / metabolism*
-
TNF-Related Apoptosis-Inducing Ligand
-
Tumor Necrosis Factor-alpha / biosynthesis*
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Apoptosis Regulatory Proteins
-
Membrane Glycoproteins
-
TNF-Related Apoptosis-Inducing Ligand
-
TNFSF10 protein, human
-
Tumor Necrosis Factor-alpha